CN1762379A - 复方硫酸氨基葡萄糖分散片制剂及其制备方法 - Google Patents
复方硫酸氨基葡萄糖分散片制剂及其制备方法 Download PDFInfo
- Publication number
- CN1762379A CN1762379A CN 200510029693 CN200510029693A CN1762379A CN 1762379 A CN1762379 A CN 1762379A CN 200510029693 CN200510029693 CN 200510029693 CN 200510029693 A CN200510029693 A CN 200510029693A CN 1762379 A CN1762379 A CN 1762379A
- Authority
- CN
- China
- Prior art keywords
- gram
- glucosamine sulfate
- glucosamine
- polyvinylpolypyrrolidone
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002849 glucosamine sulfate Drugs 0.000 title claims abstract description 48
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- -1 Compound glucosamine sulfate Chemical class 0.000 title claims abstract description 11
- 238000009472 formulation Methods 0.000 title claims description 10
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 34
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 29
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229920002472 Starch Polymers 0.000 claims abstract description 17
- 235000019698 starch Nutrition 0.000 claims abstract description 17
- 239000008107 starch Substances 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 25
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 23
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 23
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 229960004756 ethanol Drugs 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 239000000314 lubricant Substances 0.000 abstract description 3
- 239000003906 humectant Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 10
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 201000008482 osteoarthritis Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 229960002442 glucosamine Drugs 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229940021741 glucosamine hydrochloride 500 mg Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 1
- TYNLGDBUJLVSMA-UHFFFAOYSA-N 4,5-diacetyloxy-9,10-dioxo-2-anthracenecarboxylic acid Chemical compound O=C1C2=CC(C(O)=O)=CC(OC(C)=O)=C2C(=O)C2=C1C=CC=C2OC(=O)C TYNLGDBUJLVSMA-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940014797 cosamin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960004590 diacerein Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940076049 glucosamine hydrochloride 375 mg Drugs 0.000 description 1
- 229940091175 glucosamine hydrochloride 750 mg Drugs 0.000 description 1
- 229940030836 glucosamine sulfate 250 mg Drugs 0.000 description 1
- 229940021743 glucosamine sulfate 500 mg Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
致炎剂 | 给药途径 | 硫酸氨基葡萄糖 | 乙酰水杨酸 | ||||
n | ED30(mg/kg) | tmax(h) | n | ED30(mg/kg) | tmax(h) | ||
角叉菜胶 | IpPo | 6070 | 36.1380 | 11 | 2530 | 17.838.3 | 11 |
缓激肽 | Ip | 60 | >500 | 1~5 | 25 | 190 | 5 |
葡聚糖 | Ip | 45 | 632 | 1 | 30 | 176 | 3 |
*** | Ip | 40 | 700 | 3 | 25 | 193 | 5 |
5-羟色胺 | Ip | 15 | >600 | 1~5 | 5 | >800 | 1~5 |
组织胺 | Ip | 15 | >400 | 1~3 | 5 | 300 | 1 |
对渗出液的作用 | ED30(mg/kg) | 相对强度(P值) | |
硫酸氨基葡萄糖 | 吲哚美辛 | ||
体积白细胞数目蛋白含量PGE2浓度 | 570(208~1560)418(320~546)611(171~2188)无活性 | 1.9(0.7~4.9)2.4(1.3~4.6)2.6(1.1~6.0)0.9(0.3~2.5) | 0.0030.0060.004未能测得 |
作用 | ED30(mg/kg) | 相对强度(P值) | |
硫酸氨基葡萄糖 | 吲哚美辛 | ||
渗出液体积肉芽组织重量 | 664(238~1849)631(149~2679) | 2.1(1.5~2.9)3.6(0.7~18) | 0.0030.006 |
作用 | ED30(mg/kg) | 相对强度(P值) | |
硫酸氨基葡萄糖 | 吲哚美辛 | ||
Evans蓝量注射侧足跖体积 | 531(272~1038)833(513~1521) | 2.9(1.5~6)8.4(2.5~29) | 0.0030.01 |
作用 | ED30(mg/kg) | 相对强度(P值) | |
硫酸氨基葡萄糖 | 吲哚美辛 | ||
关节炎发生率注射侧足跖体积对侧足跖体积结节数目 | 184(76~446)229(148~353)111(63~194)49(3~855) | 0.9(0.3~3)1.5(0.5~5)1.9(0.6~6)1.1(0.4~3) | 0.0050.0070.020.02 |
模型 | 给药途径 | 硫酸氨基葡萄糖 | 乙酰水杨酸 | ||
n | ED30(mg/kg) | n | ED30(mg/kg) | ||
大鼠:缓激肽所致毛细血管通透性增加 | po | 16 | >400 | 16 | 45 |
大鼠:角叉菜胶所致胸膜炎对渗出物对粒细胞浸润大鼠:***致腹膜炎小鼠:醋酸致腹膜炎 | popoippo | 30303630 | 532315738275 | 552420 | 30288.91.13 |
RX 1 | RX 2 | RX 3 | RX 4 | RX 5 | RX 6 | |
硫酸氨基葡萄糖氯化钠复盐(g)硫酸软骨素(g)淀粉(g)微晶纤维素(g)交联PVP(g)L-HPC(g)5%PVP醇无水乙醇硬脂酸镁(g)滑石粉(g) | 31.420///50Q·s//0.5 | 31.4201020/50Q·s//1 | 31.420lO2050/Q·s/1/ | 31.420101070//适量2/ | 31.420101035//适量2/ | 31.42051035//适量2/ |
微粉硅胶(g)外加交联PVP(g) | // | // | // | 2/ | /35 | /35 |
处方评价 | RX 1 | RX 2 | RX 3 | RX 4 | RX 5 | RX 6 |
颗粒休止角(α)片脆碎度(%)分散均一性 | 38°0.105>5′ | 33°0.135>5′ | 31°0.1623′15″ | 32°0.1762′10″ | 32°0.1811′20″ | 30°0.1921′ |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100296938A CN1316978C (zh) | 2005-09-15 | 2005-09-15 | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100296938A CN1316978C (zh) | 2005-09-15 | 2005-09-15 | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1762379A true CN1762379A (zh) | 2006-04-26 |
CN1316978C CN1316978C (zh) | 2007-05-23 |
Family
ID=36746838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100296938A Active CN1316978C (zh) | 2005-09-15 | 2005-09-15 | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1316978C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102150836A (zh) * | 2010-12-23 | 2011-08-17 | 烟台理博天然药物开发有限公司 | 氨糖多肽软胶囊 |
CN102228466A (zh) * | 2011-03-25 | 2011-11-02 | 上海优能慧斯生物科技有限公司 | 硫酸软骨素氨糖片 |
CN104873534A (zh) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | 一种氨基葡萄糖软骨素片及其制备工艺 |
CN110507620A (zh) * | 2019-09-09 | 2019-11-29 | 山东润德生物科技有限公司 | 一种复方硫酸氨基葡萄糖分散片及其制备方法 |
-
2005
- 2005-09-15 CN CNB2005100296938A patent/CN1316978C/zh active Active
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102150836A (zh) * | 2010-12-23 | 2011-08-17 | 烟台理博天然药物开发有限公司 | 氨糖多肽软胶囊 |
CN102150836B (zh) * | 2010-12-23 | 2012-08-08 | 烟台理博天然药物开发有限公司 | 氨糖多肽软胶囊 |
CN102228466A (zh) * | 2011-03-25 | 2011-11-02 | 上海优能慧斯生物科技有限公司 | 硫酸软骨素氨糖片 |
CN104873534A (zh) * | 2015-04-03 | 2015-09-02 | 广东先强药业有限公司 | 一种氨基葡萄糖软骨素片及其制备工艺 |
CN110507620A (zh) * | 2019-09-09 | 2019-11-29 | 山东润德生物科技有限公司 | 一种复方硫酸氨基葡萄糖分散片及其制备方法 |
CN110507620B (zh) * | 2019-09-09 | 2021-05-11 | 山东润德生物科技有限公司 | 一种复方硫酸氨基葡萄糖分散片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1316978C (zh) | 2007-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1314396C (zh) | 左旋奥硝唑在制备抗厌氧菌感染药物的应用 | |
CN1805738A (zh) | 持续释放的二甲双胍片剂 | |
CN87105828A (zh) | 苏灵大或苏灵大钠和碱的速效组合物 | |
CN101057862A (zh) | 一种防治老年性骨关节病的药物组合物 | |
CN101073563A (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
CN101062343A (zh) | 一种用于治疗皮肤瘤、癣、疣、疱疹的外用中药 | |
CN1316978C (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
CN1736471A (zh) | 一种姜制剂及其制备方法 | |
CN1827112A (zh) | 一种治疗心血管疾病的分散片及其制备方法 | |
CN1943561A (zh) | 普卢利沙星口腔崩解片及其制备方法 | |
CN1800195A (zh) | 羧酸类非甾体抗炎药与氨基葡萄糖或其盐合成的化合物及其合成方法和应用 | |
CN1742726A (zh) | 阿魏酸哌嗪口腔崩解片及其制备方法 | |
CN100341495C (zh) | 格列本脲固体分散体、口服组合物及其制备方法 | |
CN1314400C (zh) | 复方甲氧那明口服固体制剂及其制备方法 | |
CN1038473C (zh) | 草乌甲素口服剂型 | |
CN1107501C (zh) | 阿苯达唑乳剂 | |
CN1490016A (zh) | 一种用于治疗病毒性肝炎的栓剂及其制备方法 | |
CN1293895C (zh) | 一种喉症口腔崩解片及其制备方法 | |
CN1621044A (zh) | 一种预防和治疗关节炎的组合物、含有该组合物制剂及其制备工艺和用途 | |
CN101066252A (zh) | 氨基葡萄糖钙片制剂及其制备方法 | |
CN1271995C (zh) | 一种心痛宁口腔崩解片及其制备方法 | |
CN1270703C (zh) | 盐酸非洛普的缓释制剂及其制备方法 | |
CN1231175A (zh) | 氟酰褪黑素及其组合物和制剂 | |
CN1278705C (zh) | 一种通心络口腔崩解片及其制备方法 | |
CN1528293A (zh) | 马来酸替加色罗滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guangdong Yipinhong Pharmacy Co.,Ltd. Assignor: Li Hanxiong Contract fulfillment period: 2008.2.5 to 2013.2.4 Contract record no.: 2009440000479 Denomination of invention: Compound glucosamine sulfate dispersible tablet formulation and its preparation method Granted publication date: 20070523 License type: Exclusive license Record date: 20090619 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.2.5 TO 2013.2.4; CHANGE OF CONTRACT Name of requester: GUANGDONG YIPINHONG PHARMACEUTICAL CO., LTD. Effective date: 20090619 |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU VANKING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LI HANXIONG Effective date: 20130329 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 518026 SHENZHEN, GUANGDONG PROVINCE TO: 510730 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130329 Address after: 510730 Guangdong Province east of Guangzhou economic and Technological Development Zone No. 6 self building Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 518026, Shenzhen City, Guangdong province Futian District Tian Village oasis city garden 5 15B Patentee before: Li Hanxiong |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Ren Jinshan Inventor after: Peng Tao Inventor after: Yang Dongling Inventor after: Zhao Hui Inventor before: Ren Jinshan Inventor before: Peng Tao Inventor before: Yang Dongling Inventor before: Zhao Hui |
|
TR01 | Transfer of patent right |
Effective date of registration: 20221111 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: 510730 Building 1, No.6 Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |